一、团队名称
肿瘤生物治疗团队
二、团队组成
团队共3名教师，其中教授1名，副教授1名，讲师1名。
三、团队介绍
团队研究方向为溶瘤病毒及肿瘤免疫治疗。主要研究内容包括溶瘤病毒OH2的临床前研究及临床试验；肿瘤免疫治疗的临床前及临床研究。团队固定研究人员3名，其中教授1人、副教授1人，讲师1人。研究工作覆盖医学、生物学、免疫学、药学等学科交叉领域，在溶瘤病毒领域的研究工作达到国际先进水平。
团队承担了国家重大新药创制计划科技重大专项1项，国家自然科学基金项目3项、近三年研究项目近500万元，发表SCI文章10余篇。
四、科研成果
（1）代表性的科研项目：
2018-2020，国家重大新药创制项目，《基因治疗溶瘤病毒1类新药的临床前和临床研究》，批准号：2018ZX09733002，子课题主持
2015-2018,国家自然科学基金面上项目,《择瘤繁殖并表达绿色荧光蛋白的单纯疱疹病毒检测循环肿瘤细胞》,批准号：81472013,72万,项目负责人
2014-2017,“十二五”国家科技支撑计划,《恶性肿瘤靶基因捕获技术等转化医学平台》,批准号：2014BAI09B04,262万,子课题负责人
2012-2015, 973,项目《恶性肿瘤免疫负调控网络》,批准号：2012CB917104，140万，子课题负责人
2012-2015, 863,项目《疫苗研发关键技术及产品研发》,批准号：2012AA02A407, 37,子课题负责人
2013.1-2014.12,国自然海外及港澳合作项目,《溶瘤病毒模拟急性感染以改善肿瘤微环境增加慢病毒肿瘤疫苗的抗瘤效果》,批准号：81228015,20,项目负责人
2012.1-2015.12,国家自然科学基金面上项目,《表达人端粒酶趋化抗原的溶瘤性单纯疱疹病毒的抗肿瘤机制研究》,批准号：81172160,60,项目负责人
（2）代表性论文：
1. Wen Zhang, Xiao Hu, Jing Liang, Yujie Zhu, Beibei Zeng, Lin Feng, Changyun Zhao, Shangmei Liu, Binlei Liu*, and Kaitai Zhang. oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity. Molecular Therapy Oncolytics, 2020, vol. 16
2. Han Hu, Ziyi Zhang, Runyang Wang, Yang Wang, Jing Jin, Linkang Cai, Junhan Yang, Haixiao Duan, Zhen Wu, Zhizheng Fang, Binlei Liu*. BGC823 Cell Line with the Stable Expression of iRFP720 Retains Its Primary Properties with Promising Fluorescence Imaging Ability. DNA and Cell Biology, 2020, DOI: 10.1089/dna.2019.5057
3. Linkang Cai, Han Hu, Haixiao Duan, Yuying Li, Zongxing Zou, Kailun Luo, Ziyi Zhang, Junhan Yang, Jing Jin1, Ying Chen, Zonghuang Ke, Zongyao Fang, Qiong Liu, Xiaoqian Hong, Sheng Hu, Binlei Liu*. The construction of a new oncolytic herpes simplex virus expressing murine interleukin-15 with gene-editing technology. Journal of Medical Virology, 2020, DOI: 10.1002/jmv.25691
4. Yujie Zhu, Xiao Hu, Lin Feng, Zhenrong Yang, Lulin Zhou, Xinchun Duan, Shujun Cheng, Wen Zhang, Binlei Liu*, Kaitai Zhang. Enhanced therapeutic efficacy of a novel oncolytic herpes simplex virus type 2 encoding an antibody against programmed cell death 1. Molecular Therapy: Oncolytics, 2019, 15: 201-213. .
5. Han Hu, Runyang Wang, Ziyi Zhang, Haixiao Duan, Yang Wang, Jing Jin, Ying Chen, Zhen Wu, Zhizheng Fang, Binlei Liu*. PiggyBac-modified CD19-expressing 4T1 cell line for the evaluation of CAR construct. Int J Clin Exp Pathol., 2019, 12(7):
6. Wen Zhang*, Feifei Wang*, Xiao Hu, Jing Liang, Binlei Liu, Qi Guan, Shangmei Liu. Inhibition of colorectal cancer liver metastasis in BALB/c mice following intratumoral injection of oncolytic herpes simplex virus type 2 for the induction of specific antitumor immunity. Oncology Letters, 2019, 17: 815-822.
7. Wang Yang, Zhou Xiaobing, Wu Zhen, Hu Han, Jin Jing, Hu Yanping, Dong Yuting, Zou Jianwen, Mao Zeyong, Shi Xiaotai, Huo Yan, Lyu Jianjun, Fang Zhizheng, Zhang Wen, Zhu Yujie, Li Bo, Liu Binlei* Preclinical safety evaluation of oncolytic herpes simplex virus type 2. . Human Gene therapy, 2018, DOI: 10.1089/hum.2018.170.
8. Wang Yang, Jing Jin, Zhen Wu, Sheng Hu, Han Hu, Zhifeng Ning, Yanfei Li, Yuting Dong, JianwenZou, Zeyong Mao, Xiaotai Shi, Huajun Zheng, Shuang Dong, Fuxing Liu, Zhizheng Fang, Jiliang Wu and Binlei Liu*.Stability and anti-tumor effect of oncolytic herpes simplex virus type 2. Oncotarget, 2018, 9:24672-24683.
9. Yang HB, Peng T, Li J, Zhang W, Zhang P, Peng S, Du T, Li YF, Yan Q, Liu BL*; Treatment of colon cancer with oncolytic herpes simplex virus in preclinical models. Gene Therapy 2016, 23(5):450.
10. Zhang W, Bao L, Yang SX, Qian ZY, Dong M, Yin LY, Zhao Q, Ge KL, Deng ZL, Zhang J, Qi F, An ZX , Yu Y, Wang QB, Wu RH, Fan F, Zhang LF, Chen XP, Na YJ , Feng L, Li J, Zhang Y, Dong Y, Zhang SR, Zhang YH , Zhang XQ , Wang J, Yi X, Zou L, Xin HW, Ditzel HJ, Gao H, Zhang KT, Liu BL*, Cheng SJ; Tumor-selective replication herpes simplex virus-based technology significantly improves clinical detection and prognostication of viable circulating tumor cells. Oncotarget 2016, 7(26):39768.
五、研究生毕业去向
1、硕士研究生：
去向为攻读博士学位或在生物医药高新技术企业就业。
六、联系方式
联系人：汪洋
邮箱：wangyang@hbut.edu.cn
